Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma
The FDA has approved Lunsumio (mosunetuzumab-axgb) to treat adults with relapsed/refractory follicular lymphoma after 2 or more lines of systemic therapy.
Diagnosis & Disease Information
ASH 2022: Trials Show Promising Results in Follicular Lymphoma
Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.
Zandelisib Plus Zanubrutinib Elicits High ORRs in Relapsed/Refractory FL or MCL
The combination of zandelisib and zanubrutinib produced high overall response rates in patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma.
Atezolizumab Does Not Improve PFS in Previously Untreated Follicular Lymphoma
Adding atezolizumab to obinutuzumab and bendamustine does not improve progression-free survival and carries an increased risk of adverse events, a study suggests.
Ultra-Low-Dose Radiation Appears Effective in Orbital Indolent B-Cell Lymphoma
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.
Mosunetuzumab Demonstrates Activity in Relapsed/Refractory Follicular Lymphoma
Mosunetuzumab produced an objective response rate of 80%.
Researchers Recommend Eliminating Bone Marrow Biopsy Requirements
Bone marrow biopsies “add little value” to response assessment in patients with follicular lymphoma, according to researchers.
Zandelisib Displays “Exemplary” Efficacy in Relapsed/Refractory Follicular Lymphoma
Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
FDA Withdraws Approval of Ukoniq Over Safety Concerns
Updated findings from the UNITY-CLL trial continue to show a possible increased risk of death among patients who received Ukoniq.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...